Further CelGro® nerve clinical trial data from all patients at 12 months, page-110

True, always good to hear other people prospective about Orthocell, personally I dont think a buyout is a option, well for the next few years. I would say a company like Johnson & Johnson or any other large Pharmaceutical who ( eventually ) partner up with Orthocell, will want a large chunk of the company weather that be directly ( the company ) or indirectly ( its share holders )

We have already been told about the next announcement this month, 12 month update Celgro Nerve and still the share price cant gain any forward traction with rubbish volumes on the buying side, and no one is willing to push the price up on the buying side. We know from past Celgro Nerve announcements we have seen some big increases in share price, 12 month updates are the next steps to approvals / partnerships. Id say early next week will be the last time to top up for increased profits

Good luck guys